Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998125 | 1.00 | ANPEP (0.57) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL291460 | 1.00 | ANPEP (0.57) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL2943529 | 1.00 | ANPEP (0.57) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Ammonia Solution, Strong SCHEMBL6107709 | 0.98 | ANPEP (0.55) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Water SCHEMBL22090286 | 0.98 | ANPEP (0.55) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Iodide SCHEMBL10818108 | 0.96 | ANPEP (0.53) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Sulfurous Acid SCHEMBL10813687 | 0.88 | ANPEP (0.47) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| SCHEMBL885265 | 0.87 | ANPEP (0.52) | ANPEPPLAUMTNR1AMTNR1BHTR1A | |
| SCHEMBL13482664 | 0.86 | TSHR (0.50) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 | |
| Vinyl Ether SCHEMBL27610276 | 0.85 | ANPEP (0.45) | ANPEPPLAUCYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617195-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2772476-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | HAMARI CHEMICALS LTD (JP) | 2017-01-11 | — | — | EP | disclosed |
| US-9174899-B2 | Method for producing optically active alcohols | HAMARI CHEMICALS, LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20140296584-A1 | Method for Producing Optically Active Alcohols | HAMARI CHEMICALS, LTD. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2772476-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Hamari Chemicals, Ltd. (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20100305212-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7531329-B2 | Carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070178565-A1 | Novel carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7220564-B2 | Carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-0757677-B1 | BENZOCYCLOHEXYLIMIDAZOLETHIONE DERIVATIVES | SYNTEX LLC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | HTR2C, HTR2A, HTR3C | ANPEP 4058/4885PLAU 4253/4885CYP1A2 1669/4885 |
| US-20070178565-A1 | Novel carbonyl reductase, gene thereof and method of using the same | PYCR1, CBR3, CBR1 | ANPEP 856/4885PLAU 3411/4885CYP1A2 1019/4885 |
| US-20140296584-A1 | Method for Producing Optically Active Alcohols | ADH5, ADH1C, ADH1A | ANPEP 2265/4885PLAU 3355/4885CYP1A2 184/4885 |
| US-20100305212-A1 | THERAPEUTIC COMPOUNDS | HTR2C, HTR3B, HTR2A | ANPEP 2952/4885PLAU 3854/4885CYP1A2 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.